ImmunoGen

NEW YORK (GenomeWeb) – Roche's Ventana Medical Systems today announced a deal with ImmunoGen to develop an immunohistochemistry-based companion diagnostic test for the oncology therapeutic firm's product candidates.

Myriad, BioMarin Ink Deal to Use HRD Test to ID Responders to PARP Inhibitor

Genomind Introduces Physician Portal for Genecept Results

The US Food and Drug Administration last week approved Roche/Genentech's latest HER2-targeting breast cancer drug, trastuzumab emtansine (T-DM1).

Biotechnology firms participating in the Alzheimer's Disease Neuroimaging Initiative have received plasma and CSF samples from ADNI participants and contributed funds for the processing of roughly 1,000 samples by biomarker discovery firm Rules-Based Medicine.

People in the News

Premium

Peter Williams

BioRegion Real Estate

Premium

Massachusetts Biotechnology Council-BioReady Communities Campaign, Alkermes Relocation, Science + Technology Park at Johns Hopkins, Ohio State University Wright Center of Innovation in Biomedical Imaging, Londonderry Clinical Translational Research and Innovation Centre, Aeras Global TB Vaccine Foundation, BioBusiness Park at Elk Run, Chrysler-University of Delaware, ICON- Qualia Clinical Services

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.